Reliability of medicaid claims versus medical record data: In a cost analysis of palivizumab

PharmacoEconomics

Volumn 25, Issue 9, 2007, Pages 793-800

  Vann, Julie Jacobson ^a   Feaganes, John ^b   Wegner, Steven ^b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b AccessCare   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILDHOOD DISEASE; COHORT ANALYSIS; COMMUNITY CARE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; HEALTH CARE ACCESS; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; INFANT; MAJOR CLINICAL STUDY; MEDICAID; MEDICAL DOCUMENTATION; MEDICAL RECORD; PEDIATRICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RELIABILITY; REPEATED DRUG DOSE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRAL RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; HEALTH CARE COSTS; HUMANS; INFANT; MEDICAID; MEDICAL RECORDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 34848818461     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725090-00007     Document Type: Article

References (45)

1. Iezzoni LI. Using administrative data to study persons with disabilities. Milbank Q 2002; 80: 347-79
2. Quam L, Ellis LBM, Venus P, et al. Using claims data for epidemiologic research. Med Care 1993; 31: 498-507
3. Cherkin DC, Deyo RA, Volinn E, et al. Use of the International Classification of Diseases (ICD-9-CM) to identify hospitalizations for mechanical low back problems in administrative databases. Spine 1992; 17: 17-25
4. Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol 1989; 42: 937-45
5. Lipowski EE, Wiederholt JB, Kreling DH, et al. Use of a Medicaid database to analyze pharmaceutical services in long-term-care facilities. Am J Hosp Pharm 1986; 43: 1467-72
6. Berkanovic E. An appraisal of Medicaid records as a data source. Med Care 1974; XII: 590-5
7. Wang PS, Walker A, Tsuang M, et al. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol 2000; 53: 571-8
8. Steinwachs DM, Stuart ME, Scholle S, et al. A comparison of ambulatory Medicaid claims to medical records: a reliability assessment. Am J Med Qual 1998; 13: 63-9
9. Federspiel CF, Ray WA, Schaffner W. Medicaid records as a valid data source: the Tennessee experience. Med Care 1976; 14: 166-72
10. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004; 57: 131-41
11. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989; 129: 837-49
12. King MA, Purdie DM, Roberts MS. Matching prescription claims with medication data for nursing home residents: implications for prescriber feedback, drug utilization studies and selection of prescription claims database. J Clin Epidemiol 2001; 54: 202-9
13. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009
14. McKenzie DA, Semradek J, McFarland BH, et al. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 2000; 53: 1248-57
15. Sena MM, Pashko S. Drug utilization review using a Medicaid claims database. Clin Ther 1993; 15: 900-4
16. Hennessy S, Bilker WB, Weber A, et al. Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf 2003; 12: 103-11
17. Grisso JA, Carson JL, Feldman HI, et al. Epidemiological pitfalls using Medicaid data in reproductive health research. J Matern Fetal Med 1997; 6: 230-6
18. Gilmer T, Kronick R, Fishman P, et al. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Care 2001; 39: 1188-202
19. Raleigh (NC): North Carolina Division of Medical Assistance, 2005. (Data on file)
20. Morrisville (NC): AccessCare, 2006 Jul 24. (Data on file)
21. MedImmune Annual Report 2005 [online]. Available from URL: http://www.medimmuni.com/ar/2005/financials/mda4.html [Accessed 2006 Aug 17]
22. Wegner S, Jacobson Vann J, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid program. Pediatrics 2004; 114 (6): 1612-9
23. Viswanathan M, King VJ, Bordley C, et al. Management of bronchiolitis in infants and children. [Evidence support/technology assessment no. 69, AHRQ publication no. 03-E014]. Rockville (MD): US Department of Health and Human Services, Agency for Healthcare Research and Quality, 2003
24. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1442-6
25. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Policy statement: prevention of respiratory syncytial virus infections. Indications for the use of palivizumab and update on the use of RSV-IGIV (RE9839). Pediatrics 1998; 102: 1211-6
26. Hennekens CH, Buring JE. Epidemiology in medicine. Boston/Toronto: Little, Brown and Company, 1987
27. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, 1981: 217-32
28. Landis JR, Koch GG. The measure of observer agreement for categorical data. Biometrics 1977; 33: 159-74
29. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 1998; 24 (4): 323-55
30. SAS/STAT software, version SAS® 9.1 (TS1M3) of the SAS System for Windows. Cary (NC): SAS Institute Inc., 2002-3
31. Mooney CZ, Duval RD. Bootstrapping: a nonparametric approach to statistical inference. Sage University Paper series on quantitative applications in the social sciences, 07-095. Newbury Park (CA): Sage University, 1993
32. SAS Institute Inc. The JackBoot macro, 2000 [online]. Available from URL: http://ftp.sas.com/techsup/download/stat/jackboot.html [Accessed 2006 Aug 31]
33. Farina D, Rodriguez SP, Bauer G, et al. Respiratory synctial virus prophylaxis: cost effective analysis in Argentina. Pediatr Infect Dis J 2002; 21 (4): 287-91
34. Lund BC, Chrischilles EA, Carter BL, et al. Development of a computer algorithm for defining an active drug list using an automated pharmacy database. J Clin Epidemiol 2003; 56: 802-6
35. Humphries KH, Rankin JM, Carere RG, et al. Co-morbidity data in outcomes research: are clinical data derived from administrative databases a reliable alternative to chart review? J Clin Epidemiol 2000; 53: 343-9
36. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004; 114 (6): 1606-11
37. Vogel AM, McKinlay MJ, Ashton T, et al. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 2002; 38 (4): 352-27
38. Schrand LM, Elliott JM, Ross MB. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother 2001; 35 (10): 534-5
39. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier. Arch Pediatr Adolesc Med 2000; 154 (1): 55-61
40. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health 2000; 36 (5): 422-7
41. Lofland JH, Touch SM, O'Connor JP, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000; 22 (11): 1357-69
42. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104 (3): 419-27
43. Marchetti A, Lau H, Magar R, et al. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther 1999; 21 (4): 752-66
44. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid's high-risk children. Arch Pediatr Adolesc Med 2002; 156: 1251-5
45. Norris CM, Ghali WA, Knudtson ML, et al. Dealing with missing data in observational health care outcomes analyses. J Clin Epidemiol 2000; 53: 377-83